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Abstract
Background: Respiratory viral infections are characterized by the infiltration of leukocytes, including
activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to
chronic lung disease. Specific mechanisms recruiting neutrophils to the lung during virus-induced lung
inflammation and injury have not been fully elucidated. Since CXCL1 and CXCL2/3, acting through
CXCR2, are potent neutrophil chemoattractants, we investigated their role in dsRNA-induced lung injury,
where dsRNA (Poly IC) is a well-described synthetic agent mimicking acute viral infection.
Methods: We used 6–8 week old female BALB/c mice to intratracheally inject either single-stranded
(ssRNA) or double-stranded RNA (dsRNA) into the airways. The lungs were then harvested at designated
timepoints to characterize the elicited chemokine response and resultant lung injury following dsRNA
exposure as demonstrated qualititatively by histopathologic analysis, and quantitatively by FACS, protein,
and mRNA analysis of BAL fluid and tissue samples. We then repeated the experiments by first pretreating
mice with an anti-PMN or corresponding control antibody, and then subsequently pretreating a separate
cohort of mice with an anti-CXCR2 or corresponding control antibody prior to dsRNA exposure.
Results: Intratracheal dsRNA led to significant increases in neutrophil infiltration and lung injury in BALB/
c mice at 72 h following dsRNA, but not in response to ssRNA (Poly C; control) treatment. Expression of
CXCR2 ligands and CXCR2 paralleled neutrophil recruitment to the lung. Neutrophil depletion studies
significantly reduced neutrophil infiltration and lun g  i n j u r y  i n  r e s p o n s e  t o  d s R N A  w h e n  m i c e  w e r e
pretreated with an anti-PMN monoclonal Ab. Furthermore, inhibition of CXCR2 ligands/CXCR2
interaction by pretreating dsRNA-exposed mice with an anti-CXCR2 neutralizing Ab also significantly
attenuated neutrophil sequestration and lung injury.
Conclusion: These findings demonstrate that CXC chemokine ligand/CXCR2 biological axis is critical
during the pathogenesis of dsRNA-induced lung injury relevant to acute viral infections.
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Background
Viral infections of the respiratory tract are a cause of the
common cold and flu in children and adults. These infec-
tions may predispose certain patients to develop chronic
respiratory disorders such as asthma, chronic obstructive
pulmonary disease (COPD), pulmonary fibrosis, and
bronchopulmonary dysplasia (BPD) [1]. Clinical symp-
toms include mucus secretion and altered airway reactiv-
ity and are hallmarked by the recruitment of
inflammatory cells with resultant changes to the airway
epithelial cell lining. Inflammation can also extend fur-
ther into the lung to cause parenchymal disease that is
characteristic of viral pneumonia as has been observed
recently in severe acute respiratory syndrome (SARS) [2].
Inflammatory cell recruitment in large part is elicited by
the generation of chemokines (chemotactic cytokines)
that are also important in establishing a pro-inflamma-
tory environment underlying chronic respiratory disor-
ders such as asthma, COPD, cystic fibrosis, pulmonary
fibrosis, and BPD [1,3-10].
Inflammatory changes due to viral infection result from
the host immune response rather than secondary to viral
replication or the viral particles themselves [11-15]. Viral
infections of epithelial cells are characterized by the gen-
eration of the pro-inflammatory molecule double-
stranded RNA (dsRNA) during intracellular replication of
viruses. When studied in human epithelial cell lines in
vitro, dsRNA triggers an innate immune response in host
cells via generation of cytokines and chemokines involved
in inflammatory cell recruitment. Specifically, dsRNA has
been shown to induce activation of the neutrophil chem-
oattractant, interleukin-8 (IL-8/CXCL8), and regulated on
activation, normal T cells expressed and secreted
(RANTES) [16]. In human subjects in vivo, elevated tra-
cheal IL-8/CXCL8 levels and neutrophil accumulation are
found in airways of patients with asthma, COPD, and
viral infection. While animal models in vivo have largely
studied the systemic effects of intraperitoneal dsRNA
treatment [17], there is a paucity of information on char-
acterization and role of chemokines in lung inflammation
and injury following intratracheal dsRNA instillation.
Murine KC/CXCL1 and MIP-2/CXCL2/3 are Glutamic
acid-Leucine-Arginine-positive (ELR-positive) CXC chem-
okines; are structural homologs of human GRO-α /CXCL1
and GRO-β /γ /CXCL2/3, respectively; and are functional
homologs of human CXC chemokines, such as IL-8/
CXCL8, ENA-78/CXCL5, and GRO-α /β /γ /CXCL1/2/3 [18-
21]. Both murine chemokines share the ability to signal
through a G protein-coupled receptor, CXCR2 [18-20].
Their human structural and functional homologs have
been associated with asthma, COPD, and viral infections
of the lung [22,23].
In the current study, we hypothesized that the early
inflammation and resultant lung injury from intratracheal
dsRNA treatment is due, in part, to the expression of ELR-
positive CXC chemokines through their interaction with
their major receptor, CXCR2. To test this hypothesis, we
injected dsRNA intratracheally into 6–8 week old female
BALB/c mice to measure neutrophil and chemokine
responses and resultant injury in the airway and lung tis-
sue compartments. We then blocked this response by pre-
treating animals with antibodies to specifically neutralize
neutrophil recruitment in a chemokine-dependent man-
ner and thereby decreased lung inflammation and injury.
Our animal model demonstrates the critical role of
CXCR2 ligands/CXCR2 in acute lung inflammation and
injury due to intratracheal dsRNA.
Methods
Reagents
RNA instillation: Double-stranded RNA (dsRNA, Poly IC)
and single-stranded RNA (ssRNA, Poly C) were purchased
from Sigma-Aldrich Corp. (St. Louis, Mo.) and reconsti-
tuted in sterile normal saline (20 µg/µl) and stored at 4°C
prior to use.
Enzyme-linked immunoadsorption assay (ELISA) experiments
Capture and Detection antibodies to murine KC/CXCL1
and murine MIP-2/CXCL2/3 were purchased as DuoSet®
from R&D Systems (Minneapolis, MN).
Neutralization studies: Purified rat anti-mouse Ly-6G (Gr-
1) mAb (clone RB6-8C5) was purchased from BD
Pharmingen (San Diego, CA) and was used for neutrophil
depletion studies as previously described [24]. Polyclonal
goat anti-murine CXCR2 was produced by the immuniza-
tion of a goat with a peptide containing the ligand-bind-
ing sequence Met-Gly-Glu-Phe-Lys-Val-Asp-Lys-Phe-Asn-
Ile-Glu-Asp-Phe-Phe-Ser-Gly of CXCR2 [24-31]. The goat
was immunized with CXCR2 in multiple intradermal sites
with complete Freund's adjuvant (CFA) followed by at
least 3 boosts of CXCR2 in incomplete Freund's adjuvant
(IFA) as previously described. [24-31]. Direct ELISA was
used to evaluate antisera titers, and sera was used for West-
ern blot, ELISA and neutralization assays when titers had
reached greater than 1/1,000,000. The CXCR2 protein
sequence has been shown to contain the ligand-binding
portion of the CXCR2 receptor [24-26,32]. The anti-
CXCR2 antibodies have been used previously to block
mouse CXCR2 in vivo, and has been shown to detect
CXCR2 by Western blot and fluorescence-activated cell
sorting analysis of neutrophils in vivo [24-26,32]. The
anti-CXCR2 antibody has been shown to be neutralizing
using both in vitro neutrophil chemotaxis assay and in vivo
by abrogating the influx of neutrophils into the perito-
neum of normal mice in response to exogenous ELR-pos-
itive murine CXC chemokines [24-26,32]. In vivoJournal of Inflammation 2005, 2:4 http://www.journal-inflammation.com/content/2/1/4
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administration of anti-CXCR2 antibodies inhibited pul-
monary neutrophil sequestration in murine models of
Aspergillosis, Nocardia, and Pseudomonas pneumonia
and prevented the influx of neutrophils in urine and the
kidney in a murine model of Escherichia coli urinary tract
infection [24-26,32]. Moreover, intraperitoneal adminis-
tration of this antibody did not alter peripheral blood
neutrophil counts [24-26,32]. 1 ml of antiserum against
mCXCR2 and control antibody is approximately 10 mg of
IgG.
Murine model of dsRNA-induced lung injury
We used 6–8 week old female BALB/c mice to intratrache-
ally inject either single-stranded (ssRNA) or double-
stranded RNA (dsRNA) using a modification of a previ-
ously described method [30,33-36]. Mice were anesthe-
tized with ketamine (60 mg/kg) intraperitoneally; then,
under sterile conditions, the anterior neck soft tissue was
dissected to expose the trachea and 50 µl RNA (20 µg/µl;
40 µg/g mouse wt) was injected via 26 gauge tuberculin
needle and syringe attached to a Stepper® microinjector
(Indicon, Inc., Brookfield, CT) into the trachea under
direct visualization. Immediately following the instilla-
tion, the skin was apposed and closed using tissue adhe-
sive and the mice were allowed to recover from anesthesia
prior to replacement into their cages.
In separate experiments, animals received either 1 ml of
goat polyclonal anti-murine CXCR2, 1 ml of normal goat
serum (NGS) control antibody, or 0.5 ml rat anti-mouse
Ly-6G mAb or corresponding control intraperitoneally 24
hours before intratracheal injection and daily until time
of sacrifice as previously described [37].
Lung bronchoalveolar lavage and tissue preparation
At time of sacrifice, 72 h following intratracheal dsRNA or
ssRNA treatment, mice were euthanized using intraperito-
neal Pentobarbital (100 mg/kg) and a heparinized sample
of blood was harvested. The thoracic cavity was then
exposed and lungs were perfused free of blood with 1 ml
0.9% normal saline via the spontaneously beating right
ventricle under constant pressure of 25 cm H20. A 26
gauge butterfly needle was used to cannulate the trachea
and bronchoalveolar lavage (BAL) was performed by
instilling 1 ml PBS + 5 mM EDTA solution as previously
described [38]. Lungs were lavaged under constant pres-
sure of 25 cm H20 and retrieved solutions were centri-
fuged at 900 × g for 15 min. The cell-free supernatants
were assayed by specific ELISAs and collected cells were
analyzed for total cell counts and cytospin differentials.
Lung tissue was then processed for the following: calcula-
tion of lung edema; microvascular permeability; mRNA;
ELISA analysis; and histopathological and immunohisto-
chemical analysis by fixing in 4% paraformaldehyde at 25
to 30 cm H2O pressure and embedding in paraffin.
Immunolocalization of TLR3
Paraffin-embedded tissues from dsRNA-treated and
ssRNA-treated lungs were processed for immunohisto-
chemical localization of Toll-like receptor 3 (TLR3)
expression using a method previously described [33,39].
Briefly, tissue sections were dewaxed with xylene and
rehydrated through graded concentrations of ethanol. Tis-
sue nonspecific binding sites were blocked using Power
Block® (BioGenex, San Ramon, CA). Tissue sections were
overlaid with 1:50 dilution of either control (goat) or pol-
yclonal goat anti-TLR3 antibody (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA). The tissue sections were washed
with TRIS-buffered saline and then incubated for 60 min
with secondary biotinylated antibody. The tissue sections
were then washed in TRIS-buffered saline and incubated
with alkaline phosphatase conjugated to streptavidin
(BioGenex). Tissue sections were then incubated with
Vectastain ABC reagent (Vector Laboratories, Burlingame,
CA) followed by the peroxidase substrate, DAB reagent
(Vector Laboratories). After optimal color development,
tissue sections were immersed in sterile water, counter-
stained with Lerners hematoxyin, and cover slipped using
an aqueous mounting solution.
Total RNA isolation and real-time quantitative PCR
Total cellular RNA from lung tissue was isolated as previ-
ous described [30,31]. Total RNA was determined and 1
ug of total RNA was reversed transcribed into cDNA and
amplified using TaqMan Gene Expression Quantification
assays (Applied Biosystems (Foster City, CA) Kit
4304134). cDNA was amplified and quantified using the
TaqMan 7700 Sequence Detection System and specific
primers for murine CXCL1, murine CXCL2/3, murine
CXCR2 and a housekeeping gene18S. The primers used
were 5'-TGA-GCT-GCG-CTG-TCA-GTG-CCT-3' (sense)
and 5'-AGA-AGC-CAG-CGT-TCA-CCA-GA-3' (antisense)
for CXCL1 (259 bp) and 5'-GCT-GGC-CAC-CAA-CCA-
CCA-GG-3' (sense) and 5'-AGC-GAG-GCA-CAT-CAG-
GTA-CG-3' (antisense) for murine CXCL2/3 (359 bp).
Predeveloped assay reagents (Applied Biosystems Kit
4304134) were used for murine CXCR2 and the house-
keeping gene, 18S. Quantitative analysis of gene expres-
sion was done using the comparative CT (∆ CT) methods,
in which CT is the threshold cycle number (the minimum
number of cycles needed before the product can be
detected)[40,41]. The arithmetic formula for the ∆ CT
method is the difference in threshold cycles for a target,
(i.e., CXCR2) and an endogenous reference (i.e., house-
keeping gene 18S). The amount of target normalized to an
endogenous reference (i.e., CXCR2 in dsRNA-treated ani-
mals) and relative to a calibration normalized to an
endogenous reference (i.e., CXCR2 in ssRNA-treated con-
trols) is given by 2-∆∆ CT [40,41]. The following is an exam-
ple for comparing CXCR2 expression from dsRNA-treated
animals and ssRNA-treated controls. Both CXCR2 fromJournal of Inflammation 2005, 2:4 http://www.journal-inflammation.com/content/2/1/4
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dsRNA-treated and ssRNA-treated controls are normal-
ized to 18S: ∆∆ CT = ∆ CT (CXCR2 expression from dsRNA-
treated animals normalized to endogenous 18S)-∆ CT
(CXCR2 expression from ssRNA-treated controls normal-
ized to endogenous 18S). The calculation of 2-∆∆ CT then
gives a relative value when comparing the target with the
calibrator, which we designate in this context as fold
increase of dsRNA-treated animals to ssRNA-treated con-
trols of the target mRNA relative quantification.
Evans blue microvascular permeability and wet:dry 
analysis of lung edema
Microvascular permeability related to lung injury was
measured using a modification of the Evans blue dye
extravasation technique, as previously described [30,42].
Extravasation of Evans blue (Sigma-Aldrich) into the
extravascular compartment was used as a quantitative
measure of lung injury and changes in microvasculature
permeability. Briefly, each animal received 20 mg/kg
Evans blue (pH 7.34) by tail vein injection 3 h before sac-
rifice. At the time of sacrifice, a heparinized sample of
blood was harvested, and plasma was removed by centrif-
ugation. Six lungs from each group were perfused free of
blood with 1 ml 0.9% normal saline via the spontane-
ously beating right ventricle and removed from the tho-
racic cavity. The trachea, mainstem bronchi, and
surrounding mediastinal structures were removed. Evans
blue was extracted from pulmonary tissues after homoge-
nization in 1 ml of 0.9% normal saline. This volume was
added to 2 vol of deionized formamide and incubated at
60C for 12 h. The supernatant was separated by centrifu-
gation at 2000 × G for 30 min. Evans blue in the plasma
and lung tissue was quantitated by dual-wavelength spec-
trophotometric analysis at 620 and 740 nm [43]. This
method corrects the specimen's absorbance at 620 nm for
the absorbance of contaminating heme pigments, using
the following formula: corrected absorbance at 620 nm =
actual absorbance at 620 nm – (1.426(absorbance at 740)
+ 0.03). We calculated a permeability index by dividing
the correct pulmonary plasma Evans blue absorbance at
620 nm; this index reflects the degree of extravasation of
Evans blue into the extravascular pulmonary tissue
compartment.
To quantitate lung edema following dsRNA treatment,
wet to dry weight ratios were obtained by ligating the
lungs away from the hilum as previously described [40].
The lungs were blotted dry and weighed. They were then
desiccated by incubation at 130°C overnight in a vacuum
oven and re-weighed to determine their dry weight. The
wet to dry ratio was then calculated.
KC/CXCL1 and MIP-2/CXCL2/3 ELISAs
KC/CXCL1 or MIP-2/CXCL2/3 protein was quantitated
using a modification of a double ligand method as previ-
ously described [30,31,40,41]. Briefly, flat-bottomed 96
well microtiter plates (Nunc Immuno-Plate I 96-F) were
coated with 50 µl/well of capture antibody to murine KC/
CXCL1 or MIP-2/CXCL2/3 (2 ug/ml in sterile phosphate
buffered saline (PBS), for 12 hrs at room temperature and
then washed with phosphate buffered saline (PBS), pH
7.5, 0.05% Tween-20 (wash buffer). Microtiter plate non-
specific binding sites were blocked with 2% BSA in PBS
and incubated for 60 minutes at 37°C. Plates were
washed three times with wash buffer and samples or
standard were added, followed by incubation for 1 hour
at 37°C. Plates were washed three times and 50 µl/well of
detection antibody for murine KC/CXCL1 and MIP-2/
CXCL2/3 antibodies added, and plates were incubated for
45 minutes at 37°C. Plates were washed three times,
streptavidin-peroxidase conjugate (Jackson Laboratories,
West Grove, PA) added, and the plates incubated for 30
minutes at 37°C. Plates were washed three times and TMB
(3,3,'5,5'-tetramethylbenzidine) chromogen substrate
(Kirkegaard & Perry Laboratories, Gaithersburg, MD)
added. The plates were incubated at room temperature to
the desired extinction, and the reaction terminated with 3
M H2SO4 solution. Plates were read at 450 nm in an auto-
mated microplate reader (Bio-Tek Instruments, Inc.,
Winooski, VT). Standards were 1/2-log dilutions of either
KC/CXCL1 or MIP-2/CXCL2/3 from 100 ng to 1 pg/ml
(50 ul/well). This ELISA method consistently detected
specific chemokine concentrations in a linear fashion
greater than 50 pg/ml. KC/CXCL1 and MIP-2/CXCL2/3
were specific in our sandwich ELISA without cross-reactiv-
ity to a panel of cytokines including murine C10, JE, MIP-
1α , MIP-1β , human GROα , GROβ , GROγ , RANTES, and
members of the CXC and CC chemokine families.
FACS analysis of lung neutrophils
Whole lung single cell suspensions were made from har-
vested lungs from four mice per group using a method, as
previously described [40]. Single cell suspensions (5 × 106
cells /ml) were stained with Abs: Tricolor-conjugated (BD
Biosciences, Franklin Lakes, NJ) anti-murine CD45
(Caltag Laboratories, South San Francisco, CA), FITC-con-
jugated anti-murine MOMA-2 (macrophage surface
marker; Seratec, Raleigh, NC), R-Phycoerythrin (R-PE)
conjugated Rat anti-murine Ly-6G (neutrophil surface
marker) and R-PE-conjugated mouse anti-murine CD3e
(lymphocyte surface marker) (BD Biosciences). Dual-
color-stained cell suspensions were analyzed on a FACS-
can flow cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA) using CellQuest 3.2.1f1 software
(BD Immunocytometry Systems).
Statistical analysis
Data were analyzed using the Microsoft® Excel 2000 statis-
tical package (Microsoft Corporation, USA). Two group
comparisons were evaluated using the unpaired StudentsJournal of Inflammation 2005, 2:4 http://www.journal-inflammation.com/content/2/1/4
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t  test. Three group comparisons were evaluated by the
ANOVA test with the post hoc analysis (i.e. Bonferroni/
Dunn). Data were expressed as mean ± SEM.
Results
DsRNA induces expression of TLR3 on airway epithelial 
cells
Since in vitro studies in human epithelial cells have dem-
onstrated that dsRNA induces the generation of chemok-
ines involved in leukocyte recruitment, we performed in
vivo studies using a murine model system of intratracheal
dsRNA-induced inflammation and injury to mimic an
acute viral infection and thus dissect the mechanisms
related to this process. The putative receptor for dsRNA
has been identified as Toll-like receptor 3 (TLR3), thus we
first determined whether dsRNA treatment was associated
with expression of TLR3. Immunolocalization using goat
anti-murine TLR3 Ab showed markedly increased expres-
sion of TLR3 localized to the surface airway epithelium of
dsRNA-treated lungs as compared to ssRNA-treated con-
trols at 72 h. Specificity to TLR3 was demonstrated by lack
of staining on control goat IgG-stained sections from both
dsRNA and ssRNA-treated groups (Fig. 1).
DsRNA induces lung neutrophil infiltration
Mice treated with intratracheal dsRNA were noted to have
significant intraparenchymal and airway leukocyte infil-
tration at 72 h following treatment as compared to naïve
and ssRNA-treated controls as demonstrated by histopa-
thology (Fig. 2A). No significant differences in cellular
infiltrates were noted among the histopathologic groups
at earlier timepoints 4, 12, 24, and 48 h following dsRNA
treatment (data not shown). FACS and BAL analysis at 72
h following dsRNA treatment specifically showed that
dsRNA induced significant neutrophil recruitment com-
pared to controls (Fig. 2B and 2C).
DsRNA induces increased lung injury
To determine if the influx of neutrophils into lung airways
and parenchyma results in lung injury, we measured two
markers of lung injury to quantify changes in lung edema
and lung vascular permeability. Results showed a signifi-
cant increase in the wet:dry ratio in dsRNA-treated lungs
as compared to controls at 72 h following dsRNA treat-
ment (Fig. 3A). Similarly, measurement of the
lung:plasma extravasation ratio of Evans blue dye also
showed a significant increase in microvascular permeabil-
ity in dsRNA-treated lungs as compared to controls (Fig.
3B).
Neutrophil depletion decreases dsRNA-induced lung 
inflammation and injury
With the finding that an increase in lung neutrophils coin-
cided with an increase in lung injury in dsRNA-treated
lungs, we next attempted to determine if this was a causal
relationship by inducing neutropenia and measuring
changes in lung neutrophil influx and lung injury. Mice
were passively immunized with specific anti-mouse Ly-6G
mAb or corresponding control at -24 h as well as 0, 24,
and 48 h following dsRNA treatment. Lungs were har-
vested at 72 h and results showed that animals pretreated
with neutrophil depleting mAb had a significant decrease
in total neutrophil counts in both lung tissue and airways
as compared to controls as reflected by FACS analysis and
BAL (Fig. 4A and 4B). Importantly, BAL samples of ani-
mals pretreated with anti-mouse Ly-6G mAb antibody
showed a specific reduction in neutrophil number but no
reduction in monocyte numbers (data not shown). Fur-
thermore, neutrophil depletion resulted in decreased lung
microvascular permeability back to baseline values (Fig.
4C).
DsRNA induces elevated KC/CXCL1 and MIP-2/CXCL2/3 
mRNA and protein levels
Since neutrophil influx was shown to result in lung injury
in dsRNA-treated lungs, we next identified which specific
factors, such as chemokines, were responsible for neu-
trophil recruitment. We focused on the ELR+ chemokines
KC/CXCL1 and MIP-2/CXCL2/3, which are known to
have neutrophil chemoattractant properties. DsRNA treat-
ment resulted in significant increases in lung KC/CXCL1
mRNA levels as well as in protein levels from whole lung
homogenates and BAL when compared to controls (Fig.
5A, C, and 5E) at 72 h following dsRNA treatment. Simi-
larly, mRNA levels and lung protein expression of MIP-2/
CXCL2/3 were also significantly elevated with an increas-
ing trend noted in BAL protein from dsRNA-treated lungs
as compared to controls (Fig. 5B, D, and 5F). Levels of
CXCR2 chemokine ligands at earlier timepoints showed
only a small increase (two-fold) in the induction of KC/
CXCL1 and MIP-2/CXCL2/3 as early as 4 h following
dsRNA-exposure (data not shown), but the maximal
increase (>ten-fold for KC/CXCL1 and >four-fold for MIP-
2/CXCL2/3) occurred at 72 h following dsRNA-exposure.
DsRNA increases CXCR2 expression in lungs
CXCR2 is the shared cellular receptor for the murine CXC
chemokine ligands KC/CXCL1 and MIP-2/CXCL2/3 [18-
20]. The finding of increased levels of KC/CXCL1 and
MIP-2/CXCL2/3 associated with dsRNA-induced neu-
trophil sequestration and lung injury led us to evaluate
the expression of CXCR2 mRNA in the lungs of these ani-
mals. Lung homogenates from dsRNA-treated animals
had significantly increased CXCR2 mRNA expression as
compared to controls (Fig. 6). The expression of CXCR2
mRNA paralleled its ligand expression, neutrophil seques-
tration, and lung injury at 72 h following dsRNA treat-
ment (Figs. 2, 3, and 5).Journal of Inflammation 2005, 2:4 http://www.journal-inflammation.com/content/2/1/4
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Inhibition of CXCR2 inhibits infiltration of neutrophils and 
attenuates dsRNA-induced lung injury
To better understand the mechanism partly responsible
for dsRNA-induced lung neutrophilia and injury, we
determined whether inhibiting CXCR2 ligand interaction
with CXCR2 significantly decreased neutrophil recruit-
ment during the pathogenesis of dsRNA-induced lung
injury. Mice were passively immunized with specific neu-
tralizing anti-murine CXCR2 or with control antibody at -
24 h, as well as 0, 24, and 48 h following dsRNA
DsRNA induces expression of TLR3 on airway epithelial cells Figure 1
DsRNA induces expression of TLR3 on airway epithelial cells. Immunohistochemistry of lungs at 72 h following ssRNA or 
dsRNA treatment. Slides were stained with either control goat IgG or anti-TLR3 Ab (100X) (n = 4 mice per group).
dsRNA; Anti-TLR3 Ab dsRNA; Control Ab
ssRNA; Anti-TLR3 Ab ssRNA; Control AbJournal of Inflammation 2005, 2:4 http://www.journal-inflammation.com/content/2/1/4
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DsRNA induces lung neutrophil infiltration Figure 2
DsRNA induces lung neutrophil infiltration. (A) Histopathology of naïve lung and at 72 h following treatment with ssRNA or 
dsRNA. Representative photomicrographs with H & E staining (100X; n = 4 mice per group). (B) Total lung cells via FACS 
analysis of whole-lung single-cell suspensions at 72 h (n = 4 mice per group; *p < 0.05). (C) Total cells via BAL fluid cell count 
at 72 h (n = 4 mice per group; *p < 0.05).
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treatment. Lungs were harvested at 72 h and results
showed that BAL neutrophil counts from animals that
received anti-CXCR2 Ab were significantly reduced as
compared to control animals that received normal goat
serum (Fig. 7A). Furthermore, measurement of lung
edema and lung microvascular permeability also showed
significant decreases in wet:dry and Evans blue extravasa-
tion in mice treated with anti-CXCR2 compared to NGS-
treated controls (Fig. 7B and 7C). Finally, histopathologic
comparison of lung fields from anti-CXCR2 pretreated
mice showed marked reduction in leukocytic infiltrate as
compared to NGS-pretreated controls (Fig. 7D).
Discussion
Respiratory viral infections are characterized by a two-
component immune response comprised of an innate
component that is fully functional before viral entry into
the epithelium and an adaptive component that develops
in response to the continued presence of the virus [1]. The
innate or acute inflammatory component is associated
with a predominance of infiltrating neutrophils. While
many viral infections of the lung are self-limiting, the
associated lung injury due to this initial event may be crit-
ical in establishing a pro-inflammatory environment
underlying certain chronic respiratory disorders such as
asthma, COPD, cystic fibrosis, pulmonary fibrosis, viral
pneumonia, and bronchopulmonary dysplasia [1,3-10].
The host's inflammatory response to viral replication
leads to pulmonary pathology hallmarked by leukocyte
infiltrate and resultant microvascular leak that progresses
to lung edema and the clinical signs of pneumonia. As the
DsRNA induces lung injury Figure 3
DsRNA induces lung injury. (A) Wet:Dry ratio at 72 h (n = 6 
mice per group; *p < 0.05). (B) Evans blue permeability index 
at 72 h (n = 6 mice per group; *p < 0.05).
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Neutrophil depletion decreases dsRNA-induced lung inflam- mation and injury Figure 4
Neutrophil depletion decreases dsRNA-induced lung inflam-
mation and injury. (A) Total lung PMNs via FACS analysis of 
whole-lung single-cell suspensions at 72 h. (n = 4 mice per 
group; *p < 0.05). (B) Total PMNs via BAL fluid cell count at 
72 h (n = 4 mice per group; *p < 0.05). (C) Evans blue per-
meability index at 72 h (n = 6 mice per group; p < 0.05). Mice 
were pretreated control Ab or anti-PMN Ab at times -24, 0, 
24, and 48 h following IT dsRNA treatment.
0
0.2
0.4
0.6
0.8
1
1.2
Control Ab Anti-PMN
L
u
n
g
M
i
c
r
o
v
a
s
c
u
l
a
r
 
P
e
r
m
e
a
b
i
l
i
t
y
(
R
a
t
i
o
 
o
f
 
L
u
n
g
:
P
l
a
s
m
a
)
0
2
4
6
8
10
Control Ab Anti-PMN
T
o
t
a
l
 
L
u
n
g
P
M
N
s
(
x
 
1
0
^
6
)
0
100
200
300
400
500
Control Ab Anti-PMN
T
o
t
a
l
 
B
A
L
P
M
N
s
(
x
1
0
0
0
) *
* A
B
C *Journal of Inflammation 2005, 2:4 http://www.journal-inflammation.com/content/2/1/4
Page 9 of 14
(page number not for citation purposes)
DsRNA induces elevated KC/CXCL1 and MIP-2/CXCL2/3 mRNA and protein levels Figure 5
DsRNA induces elevated KC/CXCL1 and MIP-2/CXCL2/3 mRNA and protein levels. (A and B) Quantitative levels of CXCL1 
and CXCL2/3 mRNA, respectively, in naïve lung and at 72 h following treatment with ssRNA or dsRNA (n = 6 mice per group; 
*p < 0.05). (C and D) Quantitative levels of CXCL1 and CXCL2/3 protein, respectively, in the lungs at 72 h (n = 6 mice per 
group; *p < 0.05). (E and F) Quantitative levels of CXCL1 and CXCL2/3 protein, respectively, in BAL fluid at 72 h (n = 6 mice 
per group; *p < 0.05).
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lung injury persists or recurs with multiple subsequent
viral infections, pulmonary vascular and airway remode-
ling may occur and eventually lead to development of air-
way hyper-reactivity and/or interstitial fibrosis [44]. Viral
infections are mediated by dsRNA, a proinflammatory
molecule generated during viral replication. DsRNA binds
to its cell surface receptor, TLR3, and activates the
production of downstream gene products, such as CXC
chemokines. In this study, we hypothesized that the inter-
action between CXCR2 and ELR-positive CXC chemok-
ines expressed during dsRNA-induced lung inflammation
is critical in mediating neutrophil recruitment, a pivotal
process required for dsRNA induced lung injury in viral
infections.
Previous studies have demonstrated that mice exposed to
a live virus via intranasal inoculation generate a systemic
acute-phase response with maximal pulmonary chemok-
ine response at one week that includes both CC and CXC
chemokines and is mouse strain-dependent (response in
BALB/c greater than in C57BL/6 mice) [45,46]. A similar
study using intratracheal delivery of live virus also demon-
strated marked pulmonary pathology including mucous
cell metaplasia and airway epithelial remodeling [47].
Another study focusing specifically on the effects of intrat-
racheal dsRNA at a low dose found similar systemic
inflammatory effects but specific pulmonary effects only
when dsRNA was delivered in conjunction with IFNγ  [48].
Finally, a recent study examined the effects of inhibiting
the CC chemokine receptor, CCR1, during live-virus
exposure in mice and showed that mortality during pneu-
movirus infection was decreased [49]. The present study
extends these findings by first determining the effects of
high-dose intratracheal dsRNA alone on neutrophil
recruitment and lung injury in BALB/c mice and then
subsequently blocking these effects via inhibition of the
CXC chemokine receptor, CXCR2.
To determine the effects of dsRNA in vivo, we first charac-
terized our murine model by performing a time-course of
dsRNA to observe histopathologic changes at 0, 4, 12, 24,
48 and 72 h following intratracheal dsRNA delivery. We
used a maximal dose of dsRNA at 40 µg/g mouse wt after
initial studies at lower doses (4 µg/g and 20 µg/g) showed
minimal leukocytic infiltrate. Furthermore, we are aware
of only one other publication that describes intratracheal
dsRNA delivery that showed no effects when used alone at
low concentration (10 ug/g) [48]. Histopathological anal-
ysis demonstrated a significantly increased leukocytic
infiltrate at 72 h following intratracheal dsRNA as
compared to earlier time points. We thus chose this obser-
vation as the basis to focus upon the 72 h timepoint.
Other studies using administration of dsRNA in BALB/c
mice in vivo have also shown a maximal innate immune
response starting at 72 h following dsRNA exposure [50]
Further characterization at 72 h following intratracheal
dsRNA showed that neutrophils were a predominant cell
type and that there was an associated injury to alveolar-
capillary membrane integrity as shown by increased lung
edema and microvascular leak.
Having characterized the histopathological damage
caused by intratracheal dsRNA, we then focused on the
underlying mechanisms responsible for promoting the
inflammation and subsequent lung injury. Our findings
of a significant increase in neutrophil infiltration follow-
ing dsRNA treatment are consistent with findings from
previous studies using a live virus that also resulted in
early neutrophil infiltration [47]. In order to determine
whether neutrophil influx was causally linked to the lung
injury observed in our system, we performed studies using
a monoclonal antibody to the Ly6G antigen on the surface
of mouse granulocytes to specifically deplete neutrophils.
These results showed decreased numbers of lung neu-
trophils by FACS analysis and BAL as expected with no
reduction in monocyte number, and also showed a
decrease in lung microvascular leak and therefore
decreased lung injury associated with decreased neu-
trophil recruitment. However, the molecular and cellular
mechanisms involved in recruiting these neutrophils
remained to be fully elucidated.
Elegant in vitro studies have demonstrated that dsRNA can
induce IL-8 expression from human bronchial epithelial
cells [16]. Furthermore, in vivo studies using live virus
DsRNA increases CXCR2 expression in lungs Figure 6
DsRNA increases CXCR2 expression in lungs. Quantitative 
real-time PCR was determined by TaqMan analysis for 
CXCR2 mRNA from naïve lung and at 72 h following ssRNA 
or dsRNA treatment (n = 6 mice per group; *p < 0.05).
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Inhibition of CXCR2 inhibits dsRNA-induced neutrophil recruitment and attenuates dsRNA-induced lung injury Figure 7
Inhibition of CXCR2 inhibits dsRNA-induced neutrophil recruitment and attenuates dsRNA-induced lung injury. (A) Total 
cells via BAL fluid cell count at 72 h (n = 4; *p < 0.05). (B) Wet:Dry ratio at 72 h (n = 6 mice per group; *p < 0.05). (C) Evans 
blue permeability index at 72 h (n = 6 mice per group; *p < 0.05). (D) Histopathology of lungs at 72 h following dsRNA treat-
ment. Representative photomicrographs with H & E staining (100X; n = 4 mice per group). Mice were pretreated with normal 
goat serum (control Ab) or anti-CXCR2 Ab at times -24, 0, 24, and 48 h following IT dsRNA treatment.
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have also demonstrated that CXC chemokines are
generated during lung inflammation [45-47]. Having
demonstrated that lung injury due to intratracheal dsRNA
is dependent on neutrophil infiltration, we determined
that CXCL1 and CXCL2/3 expression was significantly
greater in the lungs of dsRNA-treated mice than in lungs
of ssRNA-treated controls. Furthermore, expression of
CXCR2 mRNA was similarly increased in parallel to the
production of both CXCL1 and CXCL2/3 ligands and neu-
trophil sequestration during dsRNA-induced lung
inflammation. Other studies of inflammatory diseases,
such as ventilator-induced lung injury, pneumonia, and
hyperoxia-induced lung injury have demonstrated the
importance of CXCR2 expression and its role in neu-
trophil recruitment during the pathogenesis of these dis-
eases [24,40,41,51]. Collectively, these studies
demonstrate that augmented levels of CXCR2 ligands are
important in the recruitment of neutrophils during the
pathogenesis of inflammatory diseases and suggest that
the interaction between CXCR2 ligands and CXCR2 may
be pivotal in the recruitment of neutrophils to the lung
during dsRNA-induced lung injury.
Based on these findings, we performed proof of principle
studies in vivo using an antibody-mediated neutralization
strategy to evaluate the direct role for CXCL1 and CXCL2/
3 ligands and their interaction with CXCR2 during the
pathogenesis of dsRNA-induced lung injury. The anti-
CXCR2 Ab-treated mice demonstrated significant reduc-
tions specific toneutrophil infiltration that were paral-
leled by a decrease in lung injury. This suggests that if
other leukocytes are recruited there are redundant path-
ways involved in their recruitment that are CXCR2-inde-
pendent. Our findings are similar to previous
neutralization studies in virus-infected mice that showed
functional antagonism to the chemokine receptor CCR1
reduced mortality [49]. Our study is the first to demon-
strate that neutralization of CXCR2 results in decreased
neutrophil recruitment and lung injury induced by intrat-
racheal dsRNA.
TLR3 is a pattern-recognition cell surface receptor that is
responsible for specifically recognizing extracellular
dsRNA [52]. It is a member of a family of toll-like recep-
tors (TLRs) that aid the host in combating infections when
microbial pathogens bind to their specific toll-like recep-
tor to trigger NFκ B and downstream generation of
cytokines and costimulatory molecules during the innate
immune attack. TLR3 thus plays an important role in host
defense against viral infections. Our study showed that
dsRNA treatment induced the expression of TLR3 on the
cell surface of airways as compared to ssRNA-treated
controls animals. The upregulation of TLR3 in dsRNA-
exposed mouse airways suggests a positive feedback sys-
tem in which epithelial cells exposed to dsRNA increase
TLR3 expression on their cell surface. A similar upregula-
tion of TLR3 has previously been described in epithelial
cells  in vitro treated with Respiratory syncytial virus
(RSV)[53]. These findings are also consistent with in vivo
studies using monoclonal antibody to TLR3 and genetic
knockout mice of TLR3 [52,54] that establish the role of
TLR3 in dsRNA recognition and raise the interesting pos-
sibility that TLR3 may be involved in the signaling path-
way mediating dsRNA induction of CXC chemokines.
Conclusion
In conclusion, we have demonstrated that the biological
axis of CXCR2 ligand/CXCR2 signaling plays a pivotal
role in mediating neutrophil recruitment and dsRNA-
induced lung injury. This mechanism may be critical for
the promotion of further lung injury and remodeling in
patients who eventually develop chronic lung diseases
such as asthma, COPD, cystic fibrosis, pulmonary fibrosis
or bronchopulmonary dysplasia. The findings of the cur-
rent study support the contention that CXCR2 ligands and
CXCR2 mediate dsRNA-induced lung injury, and may be
a therapeutic target to attenuate this pathology.
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